OPEN SOURCE GOES BIO:
Courtesy of Brian Weir, CAMBIA
This tobacco seedling, tranformed with
Though agricultural biotechnology has the potential to transform small-scale farming in developing countries, such transformation faces a major bottleneck: the intellectual property landscape. Case in point: Golden Rice, engineered to produce beta-carotene (a source of vitamin A), is subject to approximately 40 patents that initially hampered its dissemination to developing countries.
Further, if a scientist in the public sector, small biotech company, or developing country wishes to make improvements to a proprietary crop technology, the same patent jungle can make it difficult to transfer these improvements to farmers. "When you start having tens or hundreds of patents necessary to reduce to practice one idea, then it becomes untenable. And basically innovation grinds to a halt," especially for technologies that are not obviously...
A CORE TECHNOLOGY
BioForge's flagship technology is Trans-Bacter, a new technique for gene transfer to plants, which scientists developed at CAMBIA and described in February in
The CAMBIA team removed the T-DNA locus from a Ti plasmid isolated from a virulent strain of
Steven Hughes of the Center for Genomics in Society at the University of Exeter, UK, notes that the CAMBIA research has implications for the understanding of horizontal gene-transfer events, as it demonstrates that several bacterial species can transfer genes to an organism outside their phylogenetic kingdom. "
More broadly, TransBacter was developed with the intent to fall outside the scope of existing patents. As the authors note, the majority of patents covering gene transfer to plants refer specifically to
It's too early to know whether academia and industry will embrace the BIOS model. Plant geneticists in the public sector will likely be interested in the approach, says Steven Strauss, professor of forest science at Oregon State University in Corvallis. "We feel [that] unless there's something like an open-source alternative, we're just disenfranchised."
But, University of Arizona plant geneticist Richard Jorgensen notes that for many academics using proprietary technologies for research purposes, patents are not an issue because most large biotech companies don't enforce them in such cases. "The average scientist will probably have to be convinced; they may not jump at it," says Jorgensen. "But I would think anyone in a smaller company, smaller entities that don't want to be controlled by large ag-biotech companies, would be really enthusiastic about participating in something like this, because it's their ticket potentially to independence."